Κυριακή 4 Δεκεμβρίου 2016

Niraparib Slows Ovarian Cancer Progression [News in Brief]

Results from a phase III trial indicate that maintenance therapy with the PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA mutations, or of homologous recombination deficiency; however, patients who had these mutations or defective DNA repair did better.



http://ift.tt/2gXasZN

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου